TY - JOUR
T1 - Advanced safety and genetic stability in mice of a novel dna-launched venezuelan equine encephalitis virus vaccine with rearranged structural genes
AU - Johnson, Dylan M.
AU - Sokoloski, Kevin J.
AU - Jokinen, Jenny D.
AU - Pfeffer, Tia L.
AU - Chu, Yong Kyu
AU - Adcock, Robert S.
AU - Chung, Donghoon
AU - Tretyakova, Irina
AU - Pushko, Peter
AU - Lukashevich, Igor S.
N1 - Funding Information:
Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) under Award Number AI094863 (Peter Pushko, PI). Sequencing and bioinformatics support for this work provided by NIH grants P20GM103436 (Nigel Cooper, PI) and P30GM106396 (Donald Miller, PI). We thank Jihye Kim for her technical support with the RNAScope assay. The contents of this work are solely the responsibility of the authors and do not represent the official views of the NIH or the National Institute for General Medical Sciences (NIGMS).
Funding Information:
Acknowledgments: Sequencing and bioinformatics support for this work provided by NIH grants P20GM103436 (Nigel Cooper, PI) and P30GM106396 (Donald Miller, PI). We thank Jihye Kim for her technical support with the RNAScope assay. The contents of this work are solely the responsibility of the authors and do not represent the official views of the NIH or the National Institute for General Medical Sciences (NIGMS).
Funding Information:
Funding: Research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) under Award Number AI094863 (Peter Pushko, PI).
Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2020/3
Y1 - 2020/3
N2 - The safety and genetic stability of V4020, a novel Venezuelan Equine Encephalitis Virus (VEEV) vaccine based on the investigational VEEV TC-83 strain, was evaluated in mice. V4020 was generated from infectious DNA, contains a stabilizing mutation in the E2-120 glycoprotein, and includes rearrangement of structural genes. After intracranial inoculation (IC), replication of V4020 was more attenuated than TC-83, as documented by low clinical scores, inflammation, viral load in brain, and earlier viral clearance. During the first 9 days post-inoculation (DPI), genes involved in inflammation, cytokine signaling, adaptive immune responses, and apoptosis were upregulated in both groups. However, the magnitude of upregulation was greater in TC-83 than V4020 mice, and this pattern persisted till 13 DPI, while V4020 gene expression profiles declined to mock-infected levels. In addition, genetic markers of macrophages, DCs, and microglia were strongly upregulated in TC-83 mice. During five serial passages in the brain, less severe clinical manifestations and a lower viral load were observed in V4020 mice and all animals survived. In contrast, 13.3% of mice met euthanasia criteria during the passages in TC-83 group. At 2 DPI, RNA-Seq analysis of brain tissues revealed that V4020 mice had lower rates of mutations throughout five passages. A higher synonymous mutation ratio was observed in the nsP4 (RdRP) gene of TC-83 compared to V4020 mice. At 2 DPI, both viruses induced different expression profiles of host genes involved in neuro-regeneration. Taken together, these results provide evidence for the improved safety and genetic stability of the experimental V4020 VEEV vaccine in a murine model.
AB - The safety and genetic stability of V4020, a novel Venezuelan Equine Encephalitis Virus (VEEV) vaccine based on the investigational VEEV TC-83 strain, was evaluated in mice. V4020 was generated from infectious DNA, contains a stabilizing mutation in the E2-120 glycoprotein, and includes rearrangement of structural genes. After intracranial inoculation (IC), replication of V4020 was more attenuated than TC-83, as documented by low clinical scores, inflammation, viral load in brain, and earlier viral clearance. During the first 9 days post-inoculation (DPI), genes involved in inflammation, cytokine signaling, adaptive immune responses, and apoptosis were upregulated in both groups. However, the magnitude of upregulation was greater in TC-83 than V4020 mice, and this pattern persisted till 13 DPI, while V4020 gene expression profiles declined to mock-infected levels. In addition, genetic markers of macrophages, DCs, and microglia were strongly upregulated in TC-83 mice. During five serial passages in the brain, less severe clinical manifestations and a lower viral load were observed in V4020 mice and all animals survived. In contrast, 13.3% of mice met euthanasia criteria during the passages in TC-83 group. At 2 DPI, RNA-Seq analysis of brain tissues revealed that V4020 mice had lower rates of mutations throughout five passages. A higher synonymous mutation ratio was observed in the nsP4 (RdRP) gene of TC-83 compared to V4020 mice. At 2 DPI, both viruses induced different expression profiles of host genes involved in neuro-regeneration. Taken together, these results provide evidence for the improved safety and genetic stability of the experimental V4020 VEEV vaccine in a murine model.
KW - DNA vaccine
KW - Gene rearrangement
KW - Genetic stability
KW - Live-attenuated vaccine
KW - Reversion
KW - Safety
KW - Venezuelan equine encephalitis virus
UR - http://www.scopus.com/inward/record.url?scp=85081242593&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85081242593&partnerID=8YFLogxK
U2 - 10.3390/vaccines8010114
DO - 10.3390/vaccines8010114
M3 - Article
C2 - 32121666
AN - SCOPUS:85081242593
SN - 2076-393X
VL - 8
JO - Vaccines
JF - Vaccines
IS - 1
M1 - 114
ER -